Figure 6

CXCR4 signaling did not contribute to either chemotherapy-induced neuropathy or CB ₂ agonist efficacy. The CXCR4 antagonist AMD3100 (10 mg/kg i.p.) failed to suppress the maintenance of cisplatin- (A, C) or paclitaxel- (B, D) evoked mechanical (A, B) and cold (C, D) allodynia. The CXCR4 antagonist AMD3100 (10 mg/kg i.p.) did not alter antinociceptive efficacy of the CB₂ agonist AM1710 (5 mg/kg i.p.) in suppressing paclitaxel-induced mechanical (B) and cold (D) allodynia. ^*** P < 0.001, ^** P < 0.01, ^* P < 0.05 vs. DMSO vehicle, One-way ANOVA followed by Dunnett post hoc test. ⁺ P < 0.05 vs. DMSO vehicle, planned t-test. ^xxxP < 0.001, ^xx P < 0.01, ^x P < 0.05 vs. AM1710 (5 mg/kg), Bonferroni post hoc test. ^$$ P < 0.01, ^$ P < 0.05 vs. pre-drug baseline (−60 min), paired t-test. ^### P < 0.001 vs. baseline (BL) prior to cisplatin/paclitaxel treatment, repeated measures ANOVA.